BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-25@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Sanofi — Isatuximab SAR650984 [Apr 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Investigate the Clinical
  Benefit of Isatuximab in Combination With Bortezomib\, Lenalidomide and D
 examethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible 
 for Transplant.\nSource: https://clinicaltrials.gov/study/NCT03319667\nhtt
 ps://catalystbrief.girapphe.com/e/25?lang=en\nNot investment advice. Dates
  may change.
URL:https://catalystbrief.girapphe.com/e/25?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
